Part One · Central Nervous System & Reward
Neural Appetite Pathways and Craving Trials
Tracing how subcutaneous semaglutide engages hindbrain and hypothalamic nuclei in rodents, where cellular mechanisms remain preclinical, and what a 2025 randomized trial measured in 48 adults with alcohol use disorder.
What Rodent Brain Mapping Showed About Satiety and Palatability
Subcutaneous semaglutide acts on central appetite regulation in rodents by reaching specific hindbrain and hypothalamic nuclei. In the 2020 JCI Insight paper on rodent neural appetite pathways, Gabery and colleagues demonstrated that subcutaneous dosing in mice and rats lowered body weight through distributed central nervous system pathways by directly accessing the brainstem, the area postrema, the hypothalamic arcuate nucleus, and the parabrachial nucleus.
In those rodents, weight loss occurred through reduced food intake and modulated food preference without decreasing energy expenditure.
A 2024 review examining the mechanistic action of semaglutide summarizes its actions as a potent GLP-1 analogue and notes that much of the supporting mechanistic evidence—including adipose-tissue browning, mitochondrial biogenesis, and autophagy—is preclinical and demonstrated in rodents. Keeping that species distinction explicit prevents laboratory tissue findings from being overstated as established human physiology.
The 2025 Phase 2 Trial in Adults With Alcohol Use Disorder
In 2025, Hendershot and colleagues published a Phase 2 randomized trial in alcohol use disorder in JAMA Psychiatry. The study enrolled 48 adults with alcohol use disorder and assigned them to 9 weeks of low-dose subcutaneous semaglutide or placebo. The protocol used 0.25 mg per week for four weeks, 0.5 mg per week for four weeks, and 1.0 mg for 1 week.
In the laboratory self-administration task, low-dose semaglutide reduced alcohol self-administration measured in grams consumed compared with placebo (beta -0.48; 95% CI -0.85 to -0.11; P=0.01) and predicted greater reductions in heavy drinking over 9 weeks.
When I compare this 2025 human trial alongside the 2020 rodent neuroanatomy paper, I see how the two designs complement each other. The rodent experiments identify distributed central nervous system pathways in the brainstem, area postrema, hypothalamic arcuate nucleus, and parabrachial nucleus, while the 48-participant randomized trial tests whether low-dose subcutaneous semaglutide measurably changes laboratory alcohol self-administration and heavy drinking over 9 weeks.